PMID- 17041606
OWN - NLM
STAT- MEDLINE
DCOM- 20070118
LR  - 20131121
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 38
IP  - 11
DP  - 2006 Dec
TI  - Low mortality of children undergoing hematopoietic stem cell transplantation from 
      7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of 
      antithymocyte globulin.
PG  - 745-50
AB  - Human leukocyte antigen (HLA)-matched sibling donor hematopoietic stem cell 
      transplantation (HSCT) is available for only approximately 30% patients needing 
      HSCT. Use of alternative donors is associated with a high incidence and severity 
      of graft-versus-host disease (GVHD). Here we report our experience with GVHD 
      prophylaxis using pre-transplant rabbit antithymocyte globulin (rATG), in 
      addition to post transplant cyclosporin A and methotrexate. Seventy-five children 
      received unmanipulated grafts from 7 to 10/10 HLA allele-matched unrelated 
      donors. Median follow-up was 25 months (range, 6-65 months). Only 2/75 patients 
      (2.5%) developed acute GVHD grades III-IV, and 17/75 (25%) developed extensive 
      chronic GVHD. Overall survival was 79%. It was similar in patients receiving 
      grafts from 7 or 8/10 to 9 or 10/10 allele-matched donors, and similar in 
      patients receiving peripheral blood stem cells and marrow. Six (11%) patients 
      died owing to relapse, and 10 (13%) due to transplant-related complications. The 
      addition of rATG appears to result in a low incidence of severe GVHD and overall 
      mortality.
FAU - Sedlacek, P
AU  - Sedlacek P
AD  - Department of Pediatric Hematology and Oncology, University Hospital Motol, 
      Charles University Prague, Prague, Czech Republic. petr.sedlacek@lfmotol.cuni.cz
FAU - Formankova, R
AU  - Formankova R
FAU - Keslova, P
AU  - Keslova P
FAU - Sramkova, L
AU  - Sramkova L
FAU - Hubacek, P
AU  - Hubacek P
FAU - Krol, L
AU  - Krol L
FAU - Kulich, M
AU  - Kulich M
FAU - Stary, J
AU  - Stary J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061016
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Animals
MH  - Antilymphocyte Serum/*administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Cyclosporine/administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/*prevention & control
MH  - HLA Antigens/immunology
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*mortality
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage
MH  - Infant
MH  - Male
MH  - Methotrexate/administration & dosage
MH  - Rabbits
MH  - Transplantation, Homologous/*mortality
EDAT- 2006/10/17 09:00
MHDA- 2007/01/19 09:00
CRDT- 2006/10/17 09:00
PHST- 2006/10/17 09:00 [pubmed]
PHST- 2007/01/19 09:00 [medline]
PHST- 2006/10/17 09:00 [entrez]
AID - 1705524 [pii]
AID - 10.1038/sj.bmt.1705524 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2006 Dec;38(11):745-50. doi: 10.1038/sj.bmt.1705524. Epub 
      2006 Oct 16.